Literature DB >> 19405031

Direct recognition of LPS by human but not murine CD8+ T cells via TLR4 complex.

Mousa Komai-Koma1, Derek S Gilchrist, Damo Xu.   

Abstract

LPS comprises a major PAMP and is a key target of the immune system during bacterial infection. While LPS can be recognised by innate immune cells via the TLR4 complex, it is unknown whether T lymphocytes, especially CD8(+) T cells are also capable of doing so. We report here that naive human CD8(+) T cells, after activation by TCR stimulation, express surface TLR4 and CD14. These activated CD8(+) T cells can then secrete high concentrations of IFN-gamma, granzyme and perforin in response to LPS. These effects can be specifically inhibited using siRNA for TLR4. Furthermore, LPS can synergize with IL-12 to polarize the CD8(+) T cells into cytotoxic T-cell 1 (Tc1) that produce IFN-gamma but not IL-4, with or without TCR activation. Moreover, CD8(+)CD45RO(+) memory T cells constitutively expressed TLR4 and markedly enhanced IFN-gamma production when stimulated with LPS. In contrast, activated murine CD8(+) T cells lack TLR4 and CD14 expression and fail to respond to LPS for proliferation and cytokine production. Thus, human but not murine CD8(+) T cells are able to directly recognise bacterial LPS via LPS receptor complex and TLR4 provides a novel signal for the activation of effector and memory human CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19405031     DOI: 10.1002/eji.200838866

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  25 in total

Review 1.  Modulation of immune responses through direct activation of Toll-like receptors to T cells.

Authors:  G Liu; L Zhang; Y Zhao
Journal:  Clin Exp Immunol       Date:  2010-01-29       Impact factor: 4.330

2.  Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors.

Authors:  Jibran Ahmed; Arun Kumar; Kaushal Parikh; Asad Anwar; Bettina M Knoll; Carmelo Puccio; Hoo Chun; Michael Fanucchi; Seah H Lim
Journal:  Oncoimmunology       Date:  2018-08-20       Impact factor: 8.110

3.  Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma.

Authors:  Shailender Bhatia; Natalie J Miller; Hailing Lu; Natalie V Longino; Dafina Ibrani; Michi M Shinohara; David R Byrd; Upendra Parvathaneni; Rima Kulikauskas; Jan Ter Meulen; Frank J Hsu; David M Koelle; Paul Nghiem
Journal:  Clin Cancer Res       Date:  2018-08-09       Impact factor: 12.531

Review 4.  Intestinal microbiota and the immune system in metabolic diseases.

Authors:  Panida Sittipo; Stefani Lobionda; Yun Kyung Lee; Craig L Maynard
Journal:  J Microbiol       Date:  2018-02-28       Impact factor: 3.422

5.  Structural basis of recognition of pathogen-associated molecular patterns and inhibition of proinflammatory cytokines by camel peptidoglycan recognition protein.

Authors:  Pradeep Sharma; Divya Dube; Amar Singh; Biswajit Mishra; Nagendra Singh; Mau Sinha; Sharmistha Dey; Punit Kaur; Dipendra K Mitra; Sujata Sharma; Tej P Singh
Journal:  J Biol Chem       Date:  2011-03-21       Impact factor: 5.157

6.  Rapid Functional Decline of Activated and Memory Graft-versus-Host-Reactive T Cells Encountering Host Antigens in the Absence of Inflammation.

Authors:  Hao Wei Li; Giovanna Andreola; Alicia L Carlson; Steven Shao; Charles P Lin; Guiling Zhao; Megan Sykes
Journal:  J Immunol       Date:  2015-06-17       Impact factor: 5.422

7.  Direct TLR-2 Costimulation Unmasks the Proinflammatory Potential of Neonatal CD4+ T Cells.

Authors:  Brian D Sinnott; Byung Park; Mardi C Boer; Deborah A Lewinsohn; Christina L Lancioni
Journal:  J Immunol       Date:  2016-05-18       Impact factor: 5.422

Review 8.  TLR agonists: our best frenemy in cancer immunotherapy.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Eduardo Davila
Journal:  J Leukoc Biol       Date:  2013-03-08       Impact factor: 4.962

9.  Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Authors:  A Pato; G Eisenberg; A Machlenkin; A Margalit; G Cafri; S Frankenburg; S Merims; T Peretz; M Lotem; G Gross
Journal:  Clin Exp Immunol       Date:  2015-08-28       Impact factor: 4.330

10.  CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis.

Authors:  Girish Ramachandran; Raymond Kaempfer; Chun-Shiang Chung; Anat Shirvan; Abdullah B Chahin; John E Palardy; Nicolas A Parejo; Yaping Chen; Melissa Whitford; Gila Arad; Dalia Hillman; Ronen Shemesh; William Blackwelder; Alfred Ayala; Alan S Cross; Steven M Opal
Journal:  J Infect Dis       Date:  2014-10-09       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.